CN109528701A - A kind of chap of antibacterial therapy, the compound cream of ichthyosis and preparation method - Google Patents
A kind of chap of antibacterial therapy, the compound cream of ichthyosis and preparation method Download PDFInfo
- Publication number
- CN109528701A CN109528701A CN201811562799.8A CN201811562799A CN109528701A CN 109528701 A CN109528701 A CN 109528701A CN 201811562799 A CN201811562799 A CN 201811562799A CN 109528701 A CN109528701 A CN 109528701A
- Authority
- CN
- China
- Prior art keywords
- ichthyosis
- chap
- preparation
- compound cream
- antibacterial therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010021198 ichthyosis Diseases 0.000 title claims abstract description 27
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 18
- 239000006071 cream Substances 0.000 title claims abstract description 18
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000004202 carbamide Substances 0.000 claims abstract description 14
- 229940099259 vaseline Drugs 0.000 claims abstract description 11
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 10
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004166 Lanolin Substances 0.000 claims abstract description 10
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 10
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 10
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 10
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 10
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 10
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 10
- 229940039717 lanolin Drugs 0.000 claims abstract description 10
- 235000019388 lanolin Nutrition 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000008213 purified water Substances 0.000 claims abstract description 8
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract description 6
- 229960001727 tretinoin Drugs 0.000 claims abstract description 6
- 239000004615 ingredient Substances 0.000 claims abstract description 5
- 239000000706 filtrate Substances 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims description 5
- 238000013329 compounding Methods 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 4
- 241000100289 Lonicera confusa Species 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 150000003254 radicals Chemical class 0.000 abstract description 3
- 206010039796 Seborrhoeic keratosis Diseases 0.000 abstract description 2
- 230000001139 anti-pruritic effect Effects 0.000 abstract description 2
- 239000003908 antipruritic agent Substances 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract description 2
- 201000003385 seborrheic keratosis Diseases 0.000 abstract description 2
- 230000001954 sterilising effect Effects 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract 2
- 238000010438 heat treatment Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 17
- 239000010410 layer Substances 0.000 description 14
- 235000013877 carbamide Nutrition 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 241000905957 Channa melasoma Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000001339 epidermal cell Anatomy 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 206010040849 Skin fissures Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 210000000498 stratum granulosum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 241001570521 Lonicera periclymenum Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000411545 Punargentus Species 0.000 description 1
- 208000021326 Ritter disease Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010041929 Staphylococcal scalded skin syndrome Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- -1 aminoglycoside Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Abstract
The invention belongs to the drug fields of pharmaceutical formulation techniques and tool antibacterial action treatment treatment chap, ichthyosis, disclose a kind of chap of antibacterial therapy, the compound cream of ichthyosis and preparation method, treatment chap, ichthyosis compound cream ingredient and content are as follows: urea: 100g~300g, Tretinoin: 0.9g~1.6g, chlorogenic acid (Lonicera confusa extract): 0.2g-1.6g, lanolin: 120g~400g, atoleine: 20g~66g, vaseline: 216g~403g；800~1600mL of purified water；The preparation method comprises the following steps: taking lanolin, vaseline, atoleine heating fusing, filtering is kept for 68 DEG C~92 DEG C of temperature；Separately urea, chlorogenic acid is taken to be dissolved in suitable purified water, is heated to 30 DEG C~70 DEG C, is added in the above filtrate；Liquid side edged stirs before rear liquid is added, and is mixed evenly to room temperature.Antibacterial therapy provided by the invention chap, ichthyosis compound cream have the effect of sterilization, antipruritic and except Free Radical, there is good moisture retention to skin, can be used in chapping, ichthyosis seborrheic keratosis.
Description
Technical field
The invention belongs to field of medicine preparing technology more particularly to the compound creams of a kind of chap of antibacterial therapy, ichthyosis
And preparation method.
Background technique
Chap, ichthyosis are the relatively conventional diseases of dermatology, and chap is since dry skin cracks.More than cold, dry
Dry season betides hand, foot, also known as rhagadia manus et pedis.It is more common in facies palmaris, ten finger tips, hand side, sufficient side, heel etc., it is seen that length
Different, equal crack, less serious case are not only dry, cracking to the depth；Severe one breach is controlled as deep as corium, easy bleeding, pain and preferably nourishes flesh
Skin is moisturized.Ichthyosis is one group of heredity dyskeratosis skin disease, be mainly shown as it is epidermal cornified excessively, with particle
Layer, and stratum granulosum can it is thinning, disappear, four limbs stretch that side or skin of trunk be dry, illing skin is in fish scale or snakeskin shape, can fall off
White scurf etc. is its clinical manifestation.It chaps and shows as having dry skin with ichthyosis, is coarse, and susceptible disease in the cold, temperature
Alleviate when warm current is wet, it is easy to recur.In the treatment of both diseases, mainly by inhibiting cutin to strip off, based on hyperplasia, promoting
It is that skin restores normal moisture after being stayed into cuticlar water code insurance.But rhagadia manus et pedis caused by ichthyosis and pure
Chap causes skin lesion epidermal cell subcutaneous tissue to be easier by common since the damage of skin histology forms the breach of exposure
The invasion of skin field planting bacterium staphylococcus and streptococcus.Wherein the infection of staphylococcus aureus is most commonly seen, main former
Normal skin is greater than to the adhesive force of S. aureus L-forms because being skin lesion epidermal cell.Staphylococcus aureus is gram-positive cocci, doctor
The important pathogenic bacteria of cross infection in hospital is normally present in the nasal cavity and skin surface of human body, impaired, immune when there is skin barrier
It can cause cellulitis, scalded skin syndrome, bloodstream infection etc. when hypofunction, due to its higher virulence, invasiveness
Topically or systemically infect.In recent years, due to the extensive and unreasonable use of antibacterials, staphylococcus aureus is anti-to difference
The multidrug resistant phenomenon of bacterium drug is increasingly severe, especially the appearance of methicillin-resistant staphylococcus grape ball (MRSA), the bacterium
Not only to a variety of antibiotic resistances such as beta-lactam, aminoglycoside, tetracycline and quinolones, but also to mould through the ages
Also there is drug resistance in element, Linezolid and Daptomycin.Externally-applied ointment is usually used in the past for the treatment of the disease, wherein mainly
It is to be deposited with ingredients such as urea, the lactic acid for inhibiting skin epidermis proliferative effect, but without the drug that prevention and treatment chap, ichthyosis infect
In, patient when the bacterium infection of multidrug resistant occurs, treatment difficulty will be greatly increased, or even injure patient vitals.
Summary of the invention
In view of the problems of the existing technology, the present invention provides a kind of chaps of antibacterial therapy, the compound cream of ichthyosis
And preparation method.
The invention is realized in this way a kind of antibacterial therapy is chapped, the ingredient and content of the compound cream of ichthyosis are as follows:
Urea: 100g~300g, Tretinoin: 0.9g~1.6g, chlorogenic acid (Lonicera confusa extract): 0.2g-1.6g, wool
Rouge: 120g~400g, atoleine: 20g~66g, vaseline: 216g~403g；800~1600mL of purified water
Another object of the present invention is to provide antibacterial therapy chap, the preparation method of the compound cream of ichthyosis, the party
Method are as follows:
Step 1: the lanolin, vaseline, atoleine of certain mass is taken to heat fusing, filtering；
Step 2: it takes the urea of certain mass, chlorogenic acid to be dissolved in suitable 800~1600mL of purified water, is heated to 30
DEG C~70 DEG C, it is added in the above filtrate；
Step 3: the above compounding substances are evenly stirred until room temperature.
Further, the lanolin, vaseline, atoleine fusion temperature be 40 DEG C~70 DEG C.
Further, the mixing direction when stirring is clockwise.
In conclusion advantages of the present invention and good effect are as follows: for the drug resistance status of current bacterium, we make from malicious pair
With small, the Chinese medicine for not easily leading to bacterial resistance is started with, and the mountain with apparent bacteriostasis is added in medicament composing prescription of the present invention
Honeysuckle flower extract chlorogenic acid can effectively prevent the bacteriums such as staphylococcus, streptococcus to ichthyosis and rhagadia manus et pedis patient
Caused by bacterium infection, dramatically improve the prognosis of patient.Tool antibacterial therapy provided by the invention is chapped, the compound of ichthyosis is newborn
Cream has the effect of sterilization, antipruritic and except Free Radical, has good moisture retention to skin, can be used in chap, fish scale
Sick seborrheic keratosis.Urea, chemical component are phosphinylidyne diaminos, and because urea can make skin keratin dissolution denaturation, promote cuticula
Aquation makes dermalaxia, to mitigate chapped skin symptom.Chlorogenic acid: there is wide antibacterial action and compared with high definition
Except Free Radical.
The significant pharmacological activity of Tretinoin 1. of the invention first is that induction epidermal hyperplasia, increases stratum granulosum and stratum spinosum epidermidis
Thickness, the visible DNA synthesis of epidermal cell affected increase with silk splitting index.Tretinoin is logical in the epidermal cell differentiation later period
Influence K1, K10 keratin enzymatic hydrolysis is crossed, a polyprotein is influenced and is formed as far as silk polyprotein process and crosslinking coating and promote epidermis particle
Confluent monolayer cells break up to cuticula.
The pharmacological action of carbamide ointment, the outermost layer of skin are known as in histology by what is formed after scaly epithelium angling
" cuticular layer ".The epidermis of cuticular layer pair has powerful protective effect, and skin histology is that protection can live on one's own life in free surrounding space
Vitals.Not only the excessive evaporation of moisture in vivo had been protected, but also because its powerful regeneration function makes wound healing, and because of cutin
The nucleus of cell has disappeared, and a kind of smooth performance of the oil of band is presented in epidermis, keep the skin of people more beautiful and rich in bullet
Property.Someone says that " god " gives Chinese (yellow) one pair of good skin, and careful and rich " oiliness ", coarseer than pore is white
Kind people's U.S.A is mostly.
However Keratoderma layer also has the metabolic rule of oneself, because position, the age, gender ... difference, cuticular layer
Book thickness is also different, frequent stress, friction position (such as sole, finger, the palm) cuticular layer if it is thick, and stress it is few position it is opposite
With regard to book, this is " tender ".The cuticular layer of baby very book, is easy for being damaged.Some like to be beautiful Ms to keep the face of oneself aobvious now
Must be more delicate, beauty parlor " mill skin " is just removed, what grinds? it is exactly that cutinized surface layer mill book is some.Hardly realize that layer
Cuticular layer more can form new cuticular layer by mill fastlyer.This is called " hyperkeratinization " on pathology.(otherwise being parakeratosis)
Hyperkeratinization (skin depth) says, the cell that the cell of angling has been " death ", it is only attached on epidermis from the strict sense
Layer waits for the new cuticular layer of lower layer to replace it, and here it is those of rubs dirt scab when giving a rubdown with a damp towel.It is a kind of metabolic process,
With advancing age, this replacement is more and more slow up to journey by people, and skin also just seems more and more thick, the cuticula water content thickened
It can reduce, skin elasticity can reduce, and even be chapped from the cold.Urea, chemical component are phosphinylidyne diaminos, and because urea can make skin angle
Protein dissolution denaturation, promotes the aquation of cuticula, to make dermalaxia, to mitigate chapped skin symptom, outside this product
It can make dermalaxia with its ointment or emulsifiable paste, prevent rhagadia manus et pedis.
Detailed description of the invention
Fig. 1 be antibacterial therapy provided in an embodiment of the present invention chap, ichthyosis compound cream preparation method flow chart.
Specific embodiment
In order to make the objectives, technical solutions, and advantages of the present invention clearer, with reference to embodiments, to the present invention
It is further elaborated.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, it is not used to
Limit the present invention.
Application principle of the invention is described in detail with reference to the accompanying drawing.
Antibacterial therapy provided in an embodiment of the present invention chap, ichthyosis compound cream ingredient and content are as follows: urea:
100g~300g, Tretinoin: 0.9g~1.6g, chlorogenic acid (Lonicera confusa extract): 0.2g-1.6g, lanolin: 120g~400g,
Atoleine: 20g~66g, vaseline: 216g~403g；800~1600mL of purified water.
As shown in Figure 1, it is provided in an embodiment of the present invention treatment chap, ichthyosis compound cream the preparation method comprises the following steps:
S101: the lanolin, vaseline, atoleine of certain mass is taken to heat fusing, filtering；
S102: taking the urea of certain mass, chlorogenic acid to be dissolved in suitable purified water, is heated to 30 DEG C~70 DEG C, is added
In the above filtrate；
S103: the above compounding substances are evenly stirred until room temperature.
Lanolin provided in an embodiment of the present invention, vaseline, atoleine fusion temperature be 40 DEG C~70 DEG C.
Mixing direction when stirring provided in an embodiment of the present invention is clockwise.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all in essence of the invention
Made any modifications, equivalent replacements, and improvements etc., should all be included in the protection scope of the present invention within mind and principle.
Claims (4)
1. the compound cream of a kind of antibacterial therapy chap, ichthyosis, which is characterized in that the compound for treating chap, ichthyosis
The ingredient and content of emulsifiable paste are as follows: urea: 100g~300g, Tretinoin: 0.9g~1.6g, chlorogenic acid: 0.2g-1.6g, lanolin:
120g~400g, atoleine: 20g~66g, vaseline: 216g~403g；800~1600mL of purified water.
2. a kind of antibacterial therapy as described in claim 1 is chapped, the preparation method of the compound cream of ichthyosis, which is characterized in that
It is described treatment chap, ichthyosis compound cream the preparation method comprises the following steps:
Step 1: the lanolin, vaseline, atoleine of certain mass is taken to heat fusing, filtering；
Step 2: taking the urea of certain mass, chlorogenic acid to be dissolved in suitable purified water, is heated to 30 DEG C~70 DEG C, be added with
In upper filtrate；
Step 3: the above compounding substances are evenly stirred until room temperature.
3. antibacterial therapy as claimed in claim 2 is chapped, the preparation method of the compound cream of ichthyosis, which is characterized in that institute
State lanolin, vaseline, atoleine fusion temperature be 40 DEG C~70 DEG C.
4. antibacterial therapy as claimed in claim 2 is chapped, the preparation method of the compound cream of ichthyosis, which is characterized in that institute
Mixing direction when stirring is stated as clockwise.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811562799.8A CN109528701A (en) | 2018-12-20 | 2018-12-20 | A kind of chap of antibacterial therapy, the compound cream of ichthyosis and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811562799.8A CN109528701A (en) | 2018-12-20 | 2018-12-20 | A kind of chap of antibacterial therapy, the compound cream of ichthyosis and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109528701A true CN109528701A (en) | 2019-03-29 |
Family
ID=65855817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811562799.8A Pending CN109528701A (en) | 2018-12-20 | 2018-12-20 | A kind of chap of antibacterial therapy, the compound cream of ichthyosis and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109528701A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112402557A (en) * | 2020-12-15 | 2021-02-26 | 马玉玲 | Hand and foot rhagadia cream |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397239A (en) * | 2010-09-08 | 2012-04-04 | 朱云利 | Preparation method of oil-in-water urea ointment |
| CN105832657A (en) * | 2016-05-27 | 2016-08-10 | 湖北丽益医药科技有限公司 | Compound lactic acid ointment, preparation method and application |
| CN108635365A (en) * | 2018-07-11 | 2018-10-12 | 江苏苏赋科技发展有限公司 | A kind of emulsifiable paste and its preparation method and application for dispelling acne vulgaris |
-
2018
- 2018-12-20 CN CN201811562799.8A patent/CN109528701A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397239A (en) * | 2010-09-08 | 2012-04-04 | 朱云利 | Preparation method of oil-in-water urea ointment |
| CN105832657A (en) * | 2016-05-27 | 2016-08-10 | 湖北丽益医药科技有限公司 | Compound lactic acid ointment, preparation method and application |
| CN108635365A (en) * | 2018-07-11 | 2018-10-12 | 江苏苏赋科技发展有限公司 | A kind of emulsifiable paste and its preparation method and application for dispelling acne vulgaris |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112402557A (en) * | 2020-12-15 | 2021-02-26 | 马玉玲 | Hand and foot rhagadia cream |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aramwit et al. | Silk sericin ameliorates wound healing and its clinical efficacy in burn wounds | |
| Rockwell | Acute and chronic paronychia | |
| US11116810B2 (en) | Methods for treatment of skin and skin appendages with a linseed extract as an active agent activating the synthesis of antimicrobial peptides | |
| WO2013078550A1 (en) | Use of pullulan for alleviating the appearance of scars or scar tissue | |
| CN109528701A (en) | A kind of chap of antibacterial therapy, the compound cream of ichthyosis and preparation method | |
| ES2465476T3 (en) | Disinfectant for soft, non-alcoholic, non-irritating skin | |
| Edlich et al. | Bacterial diseases of the skin | |
| ES2684519T3 (en) | Dermatological composition based on algae and olive leaf extracts | |
| CN105169457A (en) | Cationic medical dressing and preparation method thereof | |
| ES2360706T3 (en) | USE OF COSMETIC OR THERAPEUTIC BOTULIN TOXIN TO PREVENT HAIR GROWTH. | |
| EP3621468B1 (en) | Protective sock preventing fungal type infections | |
| Yagil | Cosmeceuticals: Camel and Other Milk–Natural Skin Maintenance | |
| US10272104B2 (en) | Method for treating itch | |
| US20170035802A1 (en) | Method for treating itching | |
| JP5998399B1 (en) | Itching prevention agent | |
| CN104274633A (en) | Composition for cleaning and protecting nose | |
| Gillum et al. | Localized cutaneous infection by Scedosporium prolificans (inflatum) | |
| JP2003512089A (en) | Body hygiene absorbent article with therapeutic effect | |
| CN101507811A (en) | Wound healing agent and composition | |
| Reich et al. | Abscess | |
| Day | Healthy Living | |
| Wilson et al. | Skin Abscesses | |
| Bae et al. | Surgical correction of facial cutis verticis gyrata induced by repetitive chronic friction injury | |
| Winston et al. | Preparation for Surgery | |
| Malina | The integumentary system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |